Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

10x Genomics (TXG) EBIT Margin (2018 - 2025)

10x Genomics' EBIT Margin history spans 8 years, with the latest figure at 11.77% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 1843.0% year-over-year to 11.77%; the TTM value through Dec 2025 reached 9.49%, up 2237.0%, while the annual FY2025 figure was 9.49%, 2237.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 11.77% at 10x Genomics, up from 21.64% in the prior quarter.
  • Across five years, EBIT Margin topped out at 17.42% in Q2 2025 and bottomed at 61.7% in Q3 2023.
  • The 5-year median for EBIT Margin is 27.31% (2024), against an average of 26.12%.
  • The largest annual shift saw EBIT Margin soared 35396bps in 2021 before it plummeted -4616bps in 2022.
  • A 5-year view of EBIT Margin shows it stood at 11.03% in 2021, then plummeted by -34bps to 14.78% in 2022, then tumbled by -103bps to 30.0% in 2023, then dropped by -1bps to 30.2% in 2024, then skyrocketed by 61bps to 11.77% in 2025.
  • Per Business Quant, the three most recent readings for TXG's EBIT Margin are 11.77% (Q4 2025), 21.64% (Q3 2025), and 17.42% (Q2 2025).